🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  2. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  3. G-Pen(TM) 1 mg

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  4. G-Pump™ (glucagon infusion)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  5. G-STROPHANTHIN , The placebo vial contains NaCl 0.9% and phosphate buffer ad 1ml corresponding to the IMP except API for intravenous administration. There are no visible differences in comparison to volume, seize, exterior, colour etc. of the investigational product.

    Lacuna Pharma Pty Ltd

    Acute Heart Failure

    phase 2 small molecule active

    1 trial

  6. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  7. GHB11L1

    Atea Pharmaceuticals

    Influenza, Human

    phase 2 mab completed

    1 trial

  8. GHB16L2

    Atea Pharmaceuticals

    Influenza, Human

    phase 2 mab completed

    1 trial

  9. GHR-LRX

    IONIS PHARMACEUTICALS INC

    Acromegaly

    phase 2 small molecule completed

    1 trial

  10. GHZ339, -, Placebo to GHZ339, -, PIMECROLIMUS , TACROLIMUS , -

    Novartis Pharmaceuticals

    Moderate to severe atopic dermatitis

    phase 2 small molecule active

    1 trial

  11. GIA632

    Novartis Pharmaceuticals

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  12. GIA632, Placebo to GIA632 150 mg/mL solution for injection

    Novartis Pharmaceuticals

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  13. GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial

    Lacuna Pharma Pty Ltd

    Type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  14. GLS-5300

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 2 mab completed

    2 trials

  15. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis B

    phase 2 small molecule completed

    3 trials

  16. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HBV Infection

    phase 2 small molecule completed

    1 trial

  17. GLUCOSE 5 % B.BRAUN, solution pour perfusion, ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    subarachnoid hemorrhages of aneurysmal origin (HSAa)

    phase 2 small molecule active

    1 trial

  18. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Lacuna Pharma Pty Ltd

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  19. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  20. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  21. GTAEXS617

    RECURSION PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  22. GTB-3550 TriKE® Phase I

    GT Biopharma

    High-risk Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  23. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 2 small molecule active

    1 trial

  24. GWP42003

    Jazz Pharmaceuticals Ireland Limited

    Dyslipidemias

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources